Q-omics provides the consensus-scored ZNF226 profile across patient tissues and cancer cell-line models. ZNF226 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZNF226 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF226 RNA expression shows 21,736 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, THCA, and UVM as cancer lineages where ZNF226 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF226 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF226 survival associations across molecular data types. ZNF226 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF226 RNA expression–survival associations across cancer types. High ZNF226 expression shows unfavorable associations in UVM, LGG and ACC, but favorable associations in BLCA, BRCA and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ZNF226 RNA expression.
This table summarizes ZNF226 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF226. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF226 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in LIHC, CHOL and BLCA. The THCA box plot shows higher ZNF226 RNA expression in normal versus tumor tissue (log2 FC = −0.549, t-test p < 0.001).
This table shows molecular features associated with ZNF226 in patient tissues and cancer cell lines. In patient samples, ZNF226 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF226 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
